Q-omics provides the consensus-scored LVRN profile across patient tissues and cancer cell-line models. LVRN expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LVRN is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LVRN RNA expression shows 15,387 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where LVRN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LVRN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LVRN survival associations across molecular data types. LVRN RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LVRN RNA expression–survival associations across cancer types. High LVRN expression shows unfavorable associations in UVM, CESC, STAD, KICH, OV and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for LVRN RNA expression.
This table summarizes LVRN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LVRN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LVRN shows lower tumor expression in COAD, BRCA, THCA, BLCA and STAD and higher tumor expression in LIHC. The COAD box plot shows higher LVRN RNA expression in normal versus tumor tissue (log2 FC = −0.532, t-test p < 0.001).
This table shows molecular features associated with LVRN in patient tissues and cancer cell lines. In patient samples, LVRN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LVRN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
